Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918468 | 0.86 | HTR2C (0.34) | HTR2C | |
| Hydrochloric Acid SCHEMBL27851765 | 0.84 | HTR2C (0.33) | HTR2C | |
| SCHEMBL11968900 | 0.82 | GNAI3 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2C | |
| SCHEMBL508981 | 0.81 | HTR2C (0.39) | HTR2C | |
| SCHEMBL23719656 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29869645 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21581542 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20758573 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10259483 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24672102 | 0.76 | GNAI3 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168245-B2 | Selective protein kinase inhibitors | AB SCIENCE (FR) | 2015-10-27 | — | — | US | claimed |
| EP-2736904-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB Science (FR) | 2014-06-04 | — | — | EP | claimed |
| WO-2013014170-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2013-01-31 | — | — | WO | claimed |
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | AB SCIENCE (FR) | 2018-08-21 | — | — | US | disclosed |
| EP-3122744-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB Science (FR) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016124747-A1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2016-08-11 | — | — | WO | disclosed |
| EP-3010906-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB Science (FR) | 2016-04-27 | — | — | EP | disclosed |
| WO-2015144614-A1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-10-01 | — | — | WO | disclosed |
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014202763-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2014-12-24 | — | — | WO | disclosed |
| EP-2736904-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB Science (FR) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014170-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2013-01-31 | — | — | WO | disclosed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053455-B2 | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | SYK, ZAP70, LCK | CHRNB2 2857/4885CHRNB4 3126/4885CHRNA3 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.